Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Etienne Chatelut

Showing results (11-20 of 161) with videos related to

Pageof 17
Sort By:
Anti-Cancer Drugs|August 13, 2002
Non-linear pharmacokinetics of irinotecan in miceElisabeth Rouits, Sylvie Guichard, Pierre Canal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Long-term prospective population PK study in GIST patients--letterEtienne Chatelut, Peggy Gandia, Verena Gotta, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 5, 2020
Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a reviewMaud Maillard, Félicien Le Louedec, Fabienne Thomas, et al.
Therapie|June 22, 2007
[Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys]Fabienne Thomas, Sophie Séronie-Vivien, Laurence Malard, et al.
Therapie|August 12, 2010
[Level of evidence for therapeutic drug monitoring of carboplatin]Anne Hulin, Etienne Chatelut, Bernard Royer, et al.
Medicinal Research Reviews|May 22, 2019
Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicityMarie-Noëlle Paludetto, Florent Puisset, Etienne Chatelut, et al.
Clinical Pharmacokinetics|January 11, 2023
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical PracticeFélicien Le Louedec, Florent Puisset, Etienne Chatelut, et al.
Therapie|July 10, 2016
[Not Available]Anne Hulin, Etienne Chatelut, Bernard Royer, et al.
Therapie|August 12, 2010
[Level of evidence for therapeutic drug monitoring of cisplatin]Anne Hulin, Bernard Royer, Etienne Chatelut, et al.
Therapie|July 10, 2016
[Not Available]Anne Hulin, Bernard Royer, Etienne Chatelut, et al.
Pageof 17

Showing results (11-20 of 161) with videos related to

Sort By:
Pageof 17
Anti-Cancer Drugs|August 13, 2002
Non-linear pharmacokinetics of irinotecan in miceElisabeth Rouits, Sylvie Guichard, Pierre Canal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Long-term prospective population PK study in GIST patients--letterEtienne Chatelut, Peggy Gandia, Verena Gotta, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 5, 2020
Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a reviewMaud Maillard, Félicien Le Louedec, Fabienne Thomas, et al.
Therapie|June 22, 2007
[Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys]Fabienne Thomas, Sophie Séronie-Vivien, Laurence Malard, et al.
Therapie|August 12, 2010
[Level of evidence for therapeutic drug monitoring of carboplatin]Anne Hulin, Etienne Chatelut, Bernard Royer, et al.
Medicinal Research Reviews|May 22, 2019
Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicityMarie-Noëlle Paludetto, Florent Puisset, Etienne Chatelut, et al.
Clinical Pharmacokinetics|January 11, 2023
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical PracticeFélicien Le Louedec, Florent Puisset, Etienne Chatelut, et al.
Therapie|July 10, 2016
[Not Available]Anne Hulin, Etienne Chatelut, Bernard Royer, et al.
Therapie|August 12, 2010
[Level of evidence for therapeutic drug monitoring of cisplatin]Anne Hulin, Bernard Royer, Etienne Chatelut, et al.
Therapie|July 10, 2016
[Not Available]Anne Hulin, Bernard Royer, Etienne Chatelut, et al.
Pageof 17